EHA抢先看EHA年会摘要上 [复制链接]

年6月9日，备受血液学领域瞩目的第26届欧洲血液学协会（EHA）年会将如期而至。本次EHA与年同样采取了线上虚拟网络会的模式。北京时间5月12日23:00，大会摘要公布。小编第一时间检索出16篇中国专家在本届EHA的口头发言，以供大家参考。（按摘要号排列先后）

医院张晓辉教授团队：一种β2肾上腺素能受体激动剂纠正原发性免疫性血小板减少症辅助性T细胞极化失调

标题：AΒ2ADRENERGICRECEPTORAGONISTCORRECTSDYSREGULATEDPOLARIZATIONOFTHELPERCELLSINPRIMARYIMMUNETHROMBOCYTOPENIA

作者：GaochaoZhang,FengqiLiu,YanSu,YunHe,XiaoluZhu,HaixiaFu,XiaosuZhao,XiangyuZhao,YingjunChang,XiaohuiZhang

摘要号：S（主席研讨会）

医院潘静主任团队：供体来源CD7CAR-T细胞治疗急性T淋巴细胞白血病

标题：DONOR-DERIVEDCD7CARTCELLSFORT-CELLACUTELYMPHOBLASTICLEUKEMIA

作者：JingPan,YueTan,BipingDeng,ZhuojunLing,WeiliangSong,JinlongXu,JiajiaDuan,ZelinWang,AlexH.Chang,XiaomingFeng

摘要号：S

医院陆佩华教授团队：新型CD19/CD20合成T细胞受体和抗原受体（STAR)-T细胞治疗难治/复发性（R/R）急性B淋巴细胞白血病（B-ALL）

标题：ANOVELCD19/CD20DUALSYNTHETICT-CELLRECEPTORANDANTIGENRECEPTOR(STAR)TCELLTHERAPYFORREFRACTORYANDRELAPSED(R/R)BCELLACUTELYMPHOBLASTICLEUKEMIA(B-ALL)

作者：JunfangYang,JiashengWang,XianZhang,JingjingLi,LiYu,ZhixiaoZhou,LemeiJia,YueLiu,HongliZheng,XinLin,PeihuaLu

摘要号：S

医院潘静主任团队：序贯CD19-22CAR-T细胞治疗难治/复发性B-ALL20例患者的远期随访结果

标题：LONG-TERMFOLLOW-UPOFSEQUENTIALCD19-22CART-CELLTHERAYIN20CHILDRENWITHREFRACTORYORRELAPSEDB-ALL

作者：JingPan,KaitingTang,BipingDeng,ZhuojunLing,WeiliangSong,AlexH.Chang

摘要号：S

中国医院邱录贵教授团队、华中科技大学同医院周剑峰教授团队：新型全人源BCMA靶向CAR-T细胞治疗（CTA）复发/难治性多发性骨髓瘤的I期研究结果

标题：ANUPDATEDPHASE1STUDYOFANOVELFULLYHUMANBCMA-TARGETINGCAR-TCELLS(CTA)INPATIENTSWITHRELAPSED/REFRACTORYMULTIPLEMYELOMA

作者：ChunruiLi,DiWang,JueWang,ZhenyuLi,HeHuang,JingLiu,YongpingSong,XiZhang,DehuiZou,LiGao,YongxianHu,Ai-ningXu,WenWang,LitingChen,LiZhu,MingWu,JieZhang,JianfengZhou,LuguiQiu

摘要号：S

浙江大医院金洁教授团队：新型JAK抑制剂JAKTINIB治疗晚期骨髓纤维化：II期研究的初步结果

标题：JAKTINIB,ANOVALJAKINHIBITORINTREATMENTOFPATIENTSWITHADVANCEDMYELOFIBROSISRELIMINARYRESULTSFROMAPHASE2STUDY

作者：YiZhang,HuZhou,Zhong-XingJiang,Deng-ShuWu,Jun-LingZhuang,LiWei,QianJiang,Xiu-LiWang,Jin-WenHuang,Huan-LingZhu,Rui-JuanZhang,XinDu,FeiLi,Rui-XiangXia,FengZhang,Jian-DaHu,YanLi,YuHu,JingLiu,Cheng-HaoJin,KaiSun,Ze-PingZhou,JieJin

摘要号：S

医院*教授、医院冯继锋和吴剑秋教授等团队：卡瑞利珠单抗治疗复发或难治性经典型霍奇金淋巴瘤：多中心II期研究的3年结果

标题：CAMRELIZUMABFORRELAPSEDORREFRACTORYCLASSICALHODGKINLYMPHOMAHREE-YEAROUTCOMEOFAMULTICENTER,PHASE2STUDY

作者：JianqiuWu,YuqinSong,XinchuanChen,TongyuLin,JunningCao,YanyanLiu,YaozhongZhao,JieJin,HaiwenHuang,JiandaHu,JunLuo,LilingZhang,HongweiXue,QingyuanZhang,WeiweiWang,ChunxiaChen,JifengFeng,JunZhu

摘要号：S

医院*教授团队：替雷利珠单抗（BGB-A）治疗复发/难治性经典型霍奇金淋巴瘤：II期研究的长期随访疗效和安全性结果

标题：TISLELIZUMAB(BGB-A)FORRELAPSED/REFRACTORYCLASSICALHODGKINLYMPHOMAONG-TERMFOLLOW-UPEFFICACYANDSAFETYRESULTSFROMAPHASE2STUDY

作者：YuqinSong,QuanliGao,HuilaiZhang,LeiFan,JianfengZhou,DehuiZou,WeiLi,HaiyanYang,TingLiu,QuanshunWang,FangfangLv,HaiyiGuo,XiaZhao,JaneHuang,WilliamNovotny,YidiWang,JunZhu

摘要号：S

医院克晓燕主任团队：复发难治性DLBCL的遗传学图谱及CAR-T细治疗的疗效观察

标题：GENETICLANDSCAPESANDCURATIVEEFFECTOFCARTCELLSIMMUNOTHERAPYINRELAPSEANDREFRACTORYDLBCLS

作者：HuiShi,PeihaoZheng,KaiHu,XiaoyanKe

摘要号：S

医院周道斌教授团队：来那度胺、利妥昔单抗、大剂量甲氨蝶呤（R2-MTX）方案后来那度胺维持治疗新诊断原发性中枢神经系统淋巴瘤的IB/II期研究结果

标题：PHASEIB/IISTUDYOFLENALIDOMIDE,RITUXIMAB,HIGH-DOSEMETHOREXATE(R2-MTX)REGIMEN,FOLLOWEDBYLENALIDOMIDEMAINTAINANCEINNEWLYDIAGNOSEDPRIMARYCNSLYMPHOMA

作者：YanZhang,WeiWang,WeiZhang,DaobinZhou

摘要号：S

医院王欣教授团队：阻断NCAPD3有望作为治疗弥漫性大B细胞淋巴瘤的新方法

标题：BLOCKADEOFNCAPD3ASANOVELTHERAPEUTICAPPROACHINDIFFUSELARGEB-CELLLYMPHOMA

作者：JuanYang,XiangxiangZhou,ShunfengHu,YiqingCai,JiaruiLiu,ShuaiRen,XiaominChen,XinWang

摘要号：S

医院彭*教授团队：单细胞RNA测序鉴定免疫性血小板减少症造血干细胞和祖细胞的特征

标题：FEATURESOFHEMATOPOIETICSTEMANDPROGENITORCELLSIDENTIFIEDTHROUGHSINGLE-CELLRNASEQUENCINGINIMMUNETHROMBOCYTOPENIA

作者：彭*教授团队YanLiu,AnliLiu,JunPeng

摘要号：S

医院张晓辉教授团队：高水平雌二醇诱导免疫性血小板减少症患者孕期巨核细胞凋亡及通过MST1-FOXO1轴抑制血小板形成

标题：HIGHLEVELOFESTRADIOLINDUCESMEGAKARYOCYTEAPOPTOSISANDIMPAIRSPROPLATELETFORMATIONVIAMST1-FOXO1AXISDURINGPREGNANCYINPATIENTSWITHIMMUNETHROMBOCYTOPENIA

作者：QiChen,Feng-qiLiu,Xue-yanSun,Chen-congWang,Xiao-luZhu,YunHe,Mei-yingLiang,Jian-liuWang,Xiao-HuiZhang

摘要号：S

医院*晓*教授团队：通过上调PI3K-AKT途径恢复M1/M2巨噬细胞极化减轻同种异体移植后长期孤立性血小板减少症

标题：RESTORINGM1/M2MACROPHAGEPOLARIZATIONVIAUP-REGULATINGPI3K-AKTPATHWAYALLEVIATESPROLONGEDISOLATEDTHROMBOCYTOPENIAPOST-ALLOTRANSPLANT

作者：Hong-YanZhao,Yuan-YuanZhang,TongXing,Shu-QianTang,QiWen,Zhong-ShiLyu,MengLv,YuWang,Lan-PingXu,Xiao-HuiZhang,YuanKong,Xiao-JunHuang

摘要号：S

医院张晓辉教授团队：双硫仑通过抑制巨噬细胞焦亡减轻急性移植物抗宿主病

标题：DISULFIRAMALLEVIATESACUTEGRAFT-VERSUS-HOSTDISEASEBYINHIBITINGMACROPHAGEPYROPTOSIS

作者：Xue-YanSun,YanSu,FengqiLiu,QiChen,Xiao-JunHuang,Xiao-HuiZhang

摘要号：S

医院*晓*、常英*教授团队：一个主要基于最小可测量残留病定量动力学的综合评分系统，用于预测急性淋巴细胞白血病患者的复发

标题：ANINTEGRATIVESCORINGSYSTEMMAINLYBASEDONQUANTITATIVEDYNAMICSOFMINIMAL/MEASURABLERESIDUALDISEASEFORRELAPSEPREDICTIONINPATIENTSWITHACUTELYMPHOBLASTICLEUKEMIA

作者：RuiMa,Lan-PingXu,Xiao-HuiZhang,YuWang,HuanChen,Yu-HongChen,Feng-RongWang,WeiHan,Yu-QianSun,Chen-HuaYan,Fei-FeiTang,Xiao-DongMo,Yan-RongLiu,Kai-YanLiu,Xiao-JunHuang,Ying-JunChang

摘要号：S

如有遗漏，欢迎留言补充，谢谢！